Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.

Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed.

A significant roadblock in developing effective vaccines is the low immunogenicities of antigens for subunit vaccines. Carrier moieties are essential to conjugate with the subunit antigen, deliver the antigen to the immune cells, and to activate the immune system. However, there are only limited choices of carriers for clinical uses, which include CRM-197, tetanus toxoid, and keyhole limpet hemocyanin (KLH). With the increases in types of vaccines being developed clinically, more and more conjugate vaccines are sharing the same carrier, which can interfere with each other. Therefore, a powerful new carrier can be extremely valuable to expand the arsenal of vaccines.

Our company has developed a proprietary mutant bacteriophage Qβ (mQβ) platform technology. Head to head comparison studies of against those using the benchmark carriers have shown that our mQβ conjugates can elicit more powerful immune responses. This exciting technology is being applied to vaccines against a variety of diseases including cancer and microbial infections.

To benchmark the superiority of mQβ platform, we have performed head-to-head comparison studies of mQβ against CRM-197, KLH, and TT using a tumor associated carbohydrate antigen (TACA). The carbohydrate (glycan) antigen was conjugated with mQβ and the three benchmark carriers CRM-197, KLH and TT respectively. Anti-glycan IgG generated from immunized mice was analyzed by ELISA on day 35 after the first immunization. As shown in the Figure, the mQβ-glycan conjugate induced significantly higher average anti-glycan IgG titers than the groups of mice immunized with CRM-197-glycan, KLH-glycan and TT-glycan conjugates.

Scientific Publications

Chemical Synthesis and Immunological Evaluation of a Pentasaccharide Bearing Multiple Rare Sugars as a Potential Antipertussis Vaccine. Peng Wang, Chang-xin Huo, Shuyao Lang, Kyle Caution, Setare Tahmasebi Nick, Purnima Dubey, Rajendar Deora, and Xuefei Huang

Boosting Immunity to Small Tumor-Associated Carbohydrates with Bacteriophage Qβ Capsids. Zhaojun Yin, Marta Comellas-Aragones, Sudipa Chowdhury, Philip Bentley, Katarzyna Kaczanowska, Lbachir BenMohamed, Jeffrey C. Gildersleeve, M. G. Finn, and Xuefei Huang

Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine. Zhaojun Yin, Sudipa Chowdhury, Craig McKay, Claire Baniel, W. Shea Wright, Philip Bentley, Katarzyna Kaczanowska, Jeffrey C. Gildersleeve, M.G. Finn, Lbachir BenMohamed, and Xuefei Huang

Antitumor Humoral and T Cell Responses by Mucin‑1 Conjugates of Bacteriophage Qβ in Wild-type Mice. Zhaojun Yin, Xuanjun Wu, Katarzyna Kaczanowska,  Suttipun Sungsuwan, Marta Comellas Aragones, Christian Pett, Jin Yu, Claire Baniel, Ulrika Westerlind, M.G. Finn, and Xuefei Huang

Synthesis and Immunological Evaluation of Disaccharide Bearing MUC‑1 Glycopeptide Conjugates with Virus-like Particles. Xuanjun Wu, Craig McKay, Christian Pett, Jin Yu, Manuel Schorlemer, Sherif Ramadan, Shuyao Lang, Sandra Behren, Ulrika Westerlind, M. G. Finn, and Xuefei Huang

Synthetic and immunological studies of Salmonella Enteritidis O-antigen tetrasaccharides as potential anti-Salmonella vaccines. Chang-Xin Huo, Debashis Dhara, Scott M. Baliban, Setare Tahmasebi Nick, Zibin Tan, Raphael Simon, Anup Kumar Misra  and Xuefei Huang

Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qb, and the Induction of Anticancer Antibodies. Zhaojun Yin, Steven Dulaney, Craig S. McKay, Claire Baniel, Katarzyna Kaczanowska, Sherif Ramadan, M. G. Finn, and Xuefei Huang

Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice. Xuanjun Wu, Zhaojun Yin, Craig McKay, Christian Pett, Jin Yu, Manuel Schorlemer, Trevor Gohl, Suttipun Sungsuwan, Sherif Ramadan, Claire Baniel, Anthony Allmon, Rupali Das, Ulrika Westerlind, M. G. Finn, and Xuefei Huang

Syntheses of Salmonella Paratyphi A Associated Oligosaccharide Antigens and Development towards Anti-Paratyphoid Fever Vaccines. Debashis Dhara, Scott M Baliban, Chang-Xin Huo, Zahra Rashidijahanabad, Khandra T Sears, Setare Tahmasebi Nick, Anup Kumar Misra, Sharon M Tennant, Xuefei Huang